Abstract: The purpose of this study was to evaluate the pharmacokinetics (PK) of anti-oncostatin M (OSM) IgG1 monoclonal antibodies, CNTO 1119 and its Fc variant (CNTO 8212), which incorporates the LS(Xtend) mutation to extend terminal half-life (T 1/2 ), after a single intravenous (IV) or subcutaneous (SC) administration in cynomolgus monkeys, and to predict human PK. In study 1, single doses of CNTO 1119 and CNTO 8212 were administered IV or SC at 3 mg/kg to cynomolgus monkeys (n = 3 per group). In study 2, single doses of CNTO 8212 were administered IV at 1, 5 or 20 mg/kg, or SC at 5 mg/kg to cynomolgus monkeys (n = 5 per group). Serial blood samples were collected for assessment of serum concentrations of CNTO 1119 and/or CNTO 8212. A two-compartment population PK model with first-order elimination was utilized to simultaneously describe the serum concentrations of CNTO 1119 and CNTO 8212 over time after IV and SC administration in cynomolgus monkeys. The typical population PK parameter estimates for CNTO 1119 in cynomolgus monkeys were clearance (CL) = 2.81 mL/day/kg, volume of distribution of central compartment (V 1 ) = 31.3 mL/kg, volume of distribution of peripheral compartment (V 2 ) = 23.3 mL/kg, absolute bioavailability (F) = 0.84 and T 1/2 = 13.4 days. In comparison, the typical population PK parameter estimates for CNTO 8212 in cynomolgus monkeys were CL = 1.41 mL/day/kg, V 1 = 39.8 mL/kg, V 2 = 32.6 mL/kg, F = 0.75 and T 1/2 = 35.7 days. The mean CL of CNTO 8212 was~50% lower compared with that for CNTO 1119 in cynomolgus monkeys. The overall volume of distribution (V 1 +V 2 ) for CNTO 8212 was about 32% larger compared with that for CNTO 1119, but generally similar to the vascular volume in cynomolgus monkeys. The T 1/2 of CNTO 8212 was significantly (p < 0.05) longer by about 2.7-fold than that for CNTO 1119 in cynomolgus monkeys. Thus, the modification of the Fc portion of an anti-OSM IgG1 mAb for higher FcRn binding affinity resulted in lower systemic clearance and a longer terminal half-life in cynomolgus monkeys. CNTO 8212 demonstrated linear PK after a single IV dose (1-20 mg/kg) in cynomolgus monkeys. The predicted human PK parameters suggest that CNTO 8212 is likely to exhibit slow clearance and long terminal half-life in human beings and may likely allow less frequent dosing in the clinical setting.
Several studies have demonstrated that the neonatal Fc receptor (FcRn) is critical for maintaining immunoglobulin G (IgG) homeostasis and for extending the serum half-life of IgGs and albumin in human beings [1] . The pH-dependent FcRnmediated recycling of IgG is essential in protecting IgG from catabolism and prolonging IgG half-life [2] . Human FcRn shows high affinity for human IgG resulting to the slow elimination of human mAbs with half-lives of 2-4 weeks in human beings [3] . Additionally, the subcutaneous absorption of IgG mAbs is relatively slow and mostly incomplete [4] . Several factors including transport via the lymphatic system, pre-systemic catabolism and FcRn interaction appear to play a role to the slow subcutaneous absorption of IgG mAbs [4] . It is established that selective modification of the Fc region on mAbs, via protein engineering, may alter the binding affinity of the Fc region of IgG to FcRn and improve pharmacokinetics including the bioavailability of IgG mAbs after subcutaneous (SC) administration [4] [5] [6] [7] [8] [9] . The Fc mutations (M428L/N434S) described by Xencor, Inc. [LS(Xtend) mutation], for example, have the potential to create monoclonal antibody (mAb) with extended half-lives [6] . Zalevsky et al. [6] have shown that 2-amino acid changes through LS(Xtend) mutation increased the affinity at pH 6 for both human and cynomolgus monkey FcRn by approximately 11-fold and extended the serum halflife of an anti-VEGF mAb on the LS(Xtend) platform from 9.7 to 31.1 days in cynomolgus monkeys dosed intravenously at 4 mg/kg. Additionally, experimental data in mice indicate that increasing the binding affinity of IgG mAbs to FcRn increases the SC bioavailability [4, 5] . Deng et al. [5] have demonstrated that the SC bioavailability of IgG2a mAb variant which weakly binds to FcRn at either pH 6.0 or pH 7.4 was low (41.8%), and a variant which had the greatest increase in binding affinity at both pH 6.0 and pH 7.4 had comparable bioavailability to the wild-type antibody (86.1% versus 76.3%) in mice. These results suggest that decreased bioavailability of IgG mAb variants may be due to loss of the FcRnmediated protection from catabolism at the absorption site in mice [5] . Furthermore, Datta-Manna et al. [7] also showed that engineered mAbs with the T250Q/M428L Fc mutations that improved FcRn interactions also improved half-life or clearance of these IgG variants compared with their wild-types after IV and SC administration in cynomolgus monkeys. However, a clear effect was not observed on the SC bioavailability of engineered mAbs with the T250Q/M428L Fc mutations in cynomolgus monkeys. Thus, it appears that while FcRn interaction may play a role in determining mAb SC bioavailability, other factors including physicochemical and physiological factors may also influence the bioavailability of IgG1 mAbs after SC administration [4] [5] [6] [7] [8] [9] .
Oncostatin M is a 28-kDa soluble cytokine that is secreted by activated immune cells, and a growing body of evidence indicates that OSM plays a key role in inflammation, tissue remodelling and fibrotic diseases such as idiopathic pulmonary fibrosis [10] [11] [12] [13] . Therefore, OSM may be a potential therapeutic target for inhibiting and modulating the progression of immune-mediated inflammatory diseases such as idiopathic pulmonary fibrosis. CNTO 1119 is a highly potent human IgG1j mAb directed against oncostatin M (OSM). The LS (Xtend) mutation was used to modify the Fc region of CNTO 1119 in order to generate a variant with an extended half-life compared with the parent molecule. The longer half-life of the Fc variant was anticipated to provide less frequent dosing options in the clinical setting. As IgG mAbs are subject to catabolism as an elimination pathway, an extended half-life is expected to reduce the dosing frequency required to maintain effective serum concentrations in patients [9] . An extended half-life is likely to be more convenient for the treatment of chronic disease indications as anti-OSM mAbs are being developed for treatment of chronic immune-mediated inflammatory diseases such as idiopathic pulmonary fibrosis [3, 9] . CNTO 8212, an Fc variant of CNTO 1119, is a highly potent human IgG1j mAb directed against OSM. CNTO 8212 incorporates the LS(Xtend) mutation into the IgG1 scaffold and demonstrates approximately 7.5-fold higher affinity to human FcRn than CNTO 1119. CNTO 8212 shows biological activity by blocking both human OSM and recombinant cynomolgus monkey OSM. Both CNTO 8212 and CNTO 1119 neutralize the OSM-gp130 interaction with identical affinities for human OSM (9 pM). In addition, CNTO 8212 and CNTO 1119 were comparable in terms of antiproliferative activity in the A375-S2 proliferation assay, neutralization of cytokine release into blood induced by injection of human OSM into mice and neutralization of native human OSM, as demonstrated by their ability to increase chondrocyte proteoglycan synthesis in the macrophage-chondrocyte co-culture system (Janssen R&D, unpublished data). As part of the lead candidate selection process for an IgG1 anti-OSM mAb, it was necessary to assess the potential of LS(Xtend) mutation to generate IgG1 anti-OSM mAb with extended half-life in cynomolgus monkeys [5] [6] [7] [8] [9] [14] [15] [16] [17] . The cynomolgus monkey is the most relevant species for evaluation of PK properties of mAbs and prediction of human PK to guide dose selection before first-inhuman (FIH) studies of mAbs are initiated [18] [19] [20] [21] [22] [23] .
The primary objective of this study was to evaluate how modification of the Fc Region of an anti-OSM mAb (CNTO 1119) to its Fc variant (CNTO 8212) impacts its PK parameters in cynomolgus monkeys. The secondary objectives of this study were to thoroughly characterize the PK properties of CNTO 8212 after a single intravenous (IV) or subcutaneous (SC) injection in male cynomolgus monkeys, and to predict the human pharmacokinetics.
Materials and Methods
Study agent. CNTO 1119 and CNTO 8212 were generated at Janssen R&D (Malvern, PA, USA) and formulated in 10 mM Histidine, 8.5% sucrose, 0.04% polysorbate 80, at pH 6.0.
Pharmacokinetic studies in cynomolgus monkeys. The PK studies in cynomolgus monkeys were conducted in compliance with applicable WuXi AppTec (Jiangsu Province, China) standard operating procedures (SOPs) and generally recognized good laboratory practices and regulations on the ethical treatment of animals. All in-life procedures and animal husbandry were approved by the Institutional Animal Care and Use Committee at WuXi AppTec. Study 1. Twelve (12) na€ ıve male cynomolgus monkeys were purchased from Hainan Jingang Laboratory Animal Co., Ltd (Nayang Xintan, Fucheng, Qiongshan District, Haikou, Hainan, China). The animals weighed between 2.7 and 4.0 kg and were 2.5-4.5 years old at the initiation of dosing. The animals were randomly assigned to four dose groups (n = 3 per group). The number of animals per group and the selected doses were considered sufficient for the comparison of the PK of CNTO 1119 and CNTO 8212. On the day of dosing, a single dose of CNTO 1119 or CNTO 8212 (3 mg/kg) was administered IV or SC, and blood samples were collected on days 1 (pre-dose, 1 and 6 hr after dosing), 2, 3, 5, 7, 9, 13, 17, 24, 31, 38, 46 and 61 after dosing. The PK sampling scheme used in this study was based on known PK properties of other IgG1 mAbs in cynomolgus monkeys.
Study 2. Twenty (20) male na€ ıve cynomolgus monkeys were purchased from Hainan Jingang Laboratory Animal Co., Ltd (Nayang Xintan, Fucheng, Qiongshan District, Haikou, Hainan, China). The animals weighed between 2.8 and 3.5 kg and were 2.7-3 years old at the initiation of dosing. The animals (n = 5 per group) were randomly assigned to four groups. The number of animals per group and the selected doses were considered sufficient for the characterization of the PK of CNTO 8212. Animals in groups 1-3 received a single IV dose of 1, 5 or 20 mg/kg of CNTO 8212, respectively. Animals in Group 4 received a single SC dose of 5 mg/kg of CNTO 8212. Blood samples were collected for PK analysis from each of the animals on day 1 (pre-dose, 2 hr after dosing for IV administration or 6 hr after dosing for SC administration) and days 2, 3, 5, 8, 15, 22, 29, 43, 57, 71, 85, 99, 113 and 127. The PK sampling scheme used in this study was based on observed PK properties of CNTO 8212 in cynomolgus monkeys from study 1.
Quantification of serum CNTO 1119 and CNTO 8212 concentration. In study 1, the assay for the determination of CNTO 1119 and CNTO 8212 in cynomolgus monkey serum employed a qualified fit-for-purpose electrochemiluminescence (ECL) method utilizing the Meso Scale Discovery (MSD) technology. Commercial streptavidin-coated MSD assay plate was coated with a specific biotinylated capture antibody. Standard, quality control and unknown samples were loaded into the wells, and any CNTO 1119 and/or CNTO 8212 present was bound by the immobilized antibody. After washing away any unbound substances, a ruthenylated detection antibody specific for CNTO 1119 and CNTO 8212 was added to the wells. Only the samples that contain CNTO 1119 and/or CNTO 8212 bound to both the capture and detection antibody generated ECL signal. The plate was then washed, and a tripropylamine (TPA) containing read buffer was added to the plate. In the presence of TPA, ruthenium produced a chemiluminescent signal that was triggered when voltage was applied. The signal produced was proportional to the amount of CNTO 1119 and/or CNTO 8212 present. The intraassay (within run) precision of the quality control samples at each concentration was ≤20% CV (25% at LLOQ and ULOQ) in cynomolgus monkey serum. The lowest quantifiable concentration [lowest limit of quantification (LLOQ) 9 minimum required dilution (MRD)] of CNTO 1119 or CNTO 8212 in a sample was 0.001 lg/ mL.
In study 2, a validated electrochemiluminescent-based immunoassay (ECLIA) format from MSD â was used to quantitate concentrations of CNTO 8212 in cynomolgus monkey serum. Streptavidin-coated 96-well plates served as the binding or support surface for the assay. The assay plates were blocked for 30 min. with assay buffer. The quality control samples were thawed and diluted along with the preparation of the standard curve calibrators. The master mix buffer was prepared containing the biotinylated capture antibody and ruthenium labelled antibody.
Plates were washed on an automatic plate washer to remove the assay buffer. The master mix solution was added to the samples, standard curve calibrators or quality control samples in the appropriate wells of the plate and allowed to incubate for 2 hr at room temperature with shaking at medium speed, protected from light. After incubation, plates were washed, substrate was added and the electrochemiluminescent signal was read on the MSD â Imager 6000 reader. CNTO 8212 concentrations were determined by interpolation from the standard curve. Accuracy and precision of the method were assessed using quality control samples analysed in six independent assays over 3 days using automated liquid handling. The intra-and interassay variability was <6.3% and <10.5%, respectively, in cynomolgus monkey serum. Assay selectivity, specificity in the presence of drug target (oncostatin M) and stability for CNTO 8212 in cynomolgus monkey serum were assessed as part of validation procedure. The results demonstrated that the assay is selective for CNTO 8212 in cynomolgus monkey serum; oncostatin M concentrations in the samples that yield oncostatin M:CNTO 8212 molar ratios at 1:1 and 0:1 may negatively impact accurate quantification of CNTO 8212 in cynomolgus serum assay; and CNTO 8212 is stable in cynomolgus serum for up to 24 hr at room temperature, for up to 4 weeks at 4°C, for up to 4 weeks at À20°C and for up to 6 months at À70°C. The lowest quantifiable concentration (LLOQ x MRD) of CNTO 8212 in a sample was 0.078 lg/mL at a 1:20 dilution.
Non-compartmental pharmacokinetic analysis. The noncompartmental analysis module in WinNonlin, version 5.2.1 (Pharsight, Mountain View, CA, USA), was used to generate initial estimates of PK parameters for population pharmacokinetic modelling. The maximum serum concentration (C max ) and time to reach maximum concentration (T max ) were obtained from individual serum concentration-versus-time profiles. The area under the serum concentration-versus-time curve from time zero to infinity (AUC inf ) was obtained by linear trapezoidal method. The elimination rate constant (k z ) was determined by regression analysis of the terminal phase, and terminal half-life (T 1/2 ) was calculated as 0.693/k z . The total clearance (CL) was calculated as Dose/AUC inf , and the volume of distribution at terminal phase (V z ) was calculated as CL/k z . The absolute bioavailability (F) was calculated using AUC inf after SC dose (3 or 5 mg/kg) divided by mean AUC inf after IV dose (3 or 5 mg/kg).
Population pharmacokinetic modelling. Population pharmacokinetic model development was performed with Phoenix NLME version 1.2 (Pharsight, Mountain View, CA, USA). A two-compartment PK model with first-order elimination was used to simultaneously describe the serum concentrations of CNTO 1119 and CNTO 8212 over time after IV and SC administration in cynomolgus monkeys (using combined data from study 1 and study 2). No factor was used to correct for the apparent interstudy differences during the population PK modelling. PK data from one animal (n = 1) that tested positive for antidrug antibodies were excluded from the PK modelling. The first-order conditional estimation method with extended least squares (FOCE-ELS) was used for the modelling process. The initial estimates of the relevant pharmacokinetic parameters for compartmental PK modelling were obtained from non-compartmental analysis (NCA). The structural model was selected by comparing the diagnostic plots and the objective function value (OFV). Individual values of PK parameters were estimated by assuming the following model equation:
where P i is the parameter of interest in the ith individual without covariate effects, theta is the estimate of the population mean or the typical value of the parameter and Eta i is the deviation from the population mean for the ith individual.
Residual variability was modelled using a proportional error model as shown in equation 2.
where Cobs ij is the jth observed concentration for the ith individual, Cpred ij is the corresponding predicted concentration and Epsilon ij denotes the proportional residual error. The typical population PK parameters estimated for each mAb were clearance (CL), volume of distribution of central compartment (V 1 ), volume of distribution of peripheral compartment (V 2 ), intercompartmental clearance (CL2), first-order absorption rate constant (k a ) and absolute bioavailability (F). The terminal half-life (T 1/2 ) was also calculated.
Prediction of human pharmacokinetics. Simple allometry and/or a time-invariant method (elementary Dedrick plot) have been shown to predict human PK clearance (with optimal exponents estimated to be 0.85 or 0.90) from cynomolgus monkey data for mAbs targeting soluble receptors or membrane-bound receptors with limited tissue distribution with similar accuracy [22, 23] . In this investigation, the species time-invariant method (with fixed allometric exponent of 0.9) was used to predict the human PK profile of CNTO 1119 and CNTO 8212 after IV and SC administration in cynomolgus monkeys [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] .
The equivalent times in human (T equivalent ) were obtained from animal body-weight (BW animal ) and PK sampling time-points in cynomolgus monkeys (T animal ) as follows:
The corresponding human equivalent serum concentrations (C equivalent ) were obtained from concentrations in cynomolgus monkeys (C animal ) normalized for administered dose (Dose animal ) and cynomolgus monkeys body-weight (BW animal ) as follows:
The projected human serum concentration (C human )-versus-time (T human ) profile was constructed using the following equations:
The animals weighed between 2.7 and 4.0 kg, and a human bodyweight of 70 kg was used in the projections. The allometric exponent b was set at the empirical value of 0.9 [19, 20] .
A two-compartment model with first-order elimination was used to simultaneously describe the projected serum concentrations of CNTO 1119 and CNTO 8212 over time after IV and SC administration in human beings. The first-order conditional estimation method with extended least squares (FOCE-ELS) in Phoenix NLME 1.2 was used to calculate CL, V 1 , V 2 , CL2, k a , F and T 1/2 based on combined concentration-time profiles after IV and SC administration in cynomolgus monkeys from study 1 and study 2. The human PK parameters were calculated for a human individual (70 kg) given a single IV dose of CNTO 1119 or CNTO 8212 at 1 mg/kg.
Simulation of potential multiple dosage regimens. CNTO 1119 and CNTO 8212 were evaluated in terms of their in vitro potency; CNTO 1119 and CNTO 8212 had comparable activity in the A375-S2 proliferation assay, completely neutralizing the antiproliferative activity of 2 ng/mL human OSM with IC 50 values of 101 pM (15.2 ng/mL) and 83 pM (12.5 ng/mL), respectively. The estimated IC 90 values for CNTO 1119 and CNTO 8212 to neutralize the antiproliferative activity of human OSM were 0.14 lg/mL and 0.11 lg/mL, respectively. These values are not significantly different. After taking into account the presumed 10% distribution of mAbs from blood to the site of action in the lungs, CNTO 1119 and CNTO 8212 serum concentrations of approximately 0.1 and 1.0 lg/mL may be required to achieve a 50% and 90% of maximum neutralization of the antiproliferative activity of human OSM in the lung, respectively. Thus, based on in vitro activity of CNTO 1119 and CNTO 8212 to neutralize the antiproliferative activity of human OSM, a target trough concentration (C trough ) of about 1 lg/mL in human serum may lead to inhibition of OSM signalling in vivo. Although extrapolation of in vitro data to human individuals is unclear, dosing regimens that can maintain trough concentrations of CNTO 1119 or CNTO 8212 of ≥1.0 lg/mL in human individuals while remaining within the exposures observed at the no-observed-adverse-effect level (NOAEL) in the toxicology studies may be evaluated in clinical studies. Using the two-compartment model with first-order elimination, PK simulations were performed to determine potential SC dosing regimens that would provide C trough of ≥1.0 lg/mL in human beings.
Statistical analysis. Graphic concentration-time profiles were generated, and t-test was performed with SigmaPlot (Systat Software Inc., San Jose, CA, USA). The CNTO 8212 and CNTO 1119 PK parameters were compared using a simple t-test. A p value of <0.05 was considered statistically significant.
Results
Non-compartmental pharmacokinetic profiles of CNTO 1119 and CNTO 8218 in cynomolgus monkeys. Study 1. The mean (SD) serum concentration-versus-time profiles of CNTO 1119 and CNTO 8212 after a single IV or SC administration of 3 mg/kg in cynomolgus monkeys (n = 3) are presented in figs 1 and 2, respectively. After a single IV injection of CNTO 1119, the mean values of C max and AUC inf were 103 lg/mL and 1072 lg*day/mL, respectively. After a single SC dose of CNTO 1119 (3 mg/kg), the median T max was approximately 4 days after dosing, and the mean values of C max and AUC inf were 42.8 lg/mL and 966 lg*day/mL, respectively.
In comparison, the mean values of C max and AUC inf were 60.6 lg/mL and 1497 lg*day/mL, respectively, after the single IV injection of CNTO 8212. After a single SC dose of CNTO 8212 (3 mg/kg), the median T max was approximately 4 days after dosing, and the mean values of C max and AUC inf were 24.9 lg/mL and 1114 lg*day/mL, respectively. The C max of CNTO 1119 appeared to be higher compared with that of CNTO 8212, but the serum concentrations of CNTO 8212 during the terminal phase appeared to decline at a slower rate compared with the serum concentrations of CNTO 1119. After a single SC dose of 5 mg/kg of CNTO 8212, the median T max was approximately 4 days, and the mean C max and AUC inf values were 62.0 lg/mL and 3300 lg*day/mL, respectively.
Population pharmacokinetic modelling.
The population two-compartment model with IV infusion and SC administration, and first-order elimination (with proportional residual error model) adequately described the observed concentration-time data of CNTO 1119 and CNTO 8212 after IV and SC administration in cynomolgus monkeys (figs 4 and 5). The typical population PK parameter estimates for CNTO 1119 in cynomolgus monkeys were CL = 2.81 mL/day/kg, V 1 = 31.3 mL/kg, V 2 = 23.3 mL/kg, CL2 = 19.2 mL/day/kg, k a = 0.70 1/day, F = 0.84 and the estimated T 1/2 = 13.4 days (table 1). In comparison, the typical population PK parameter estimates for CNTO 8212 in cynomolgus monkeys were CL = 1.41 mL/day/kg, V 1 = 39.8 mL/kg, V 2 = 32.6 mL/kg, CL2 = 33.7 mL/day/kg, k a = 1.41 1/day, F = 0.75 and T 1/2 = 35.7 days (table 1). The mean CL of CNTO 8212 was about 50% lower compared with that for CNTO 1119 in cynomolgus monkeys. The overall volume of distribution (V 1 + V 2 ) for CNTO 8212 was about 32% larger compared with the corresponding value for CNTO 1119, but generally similar to the vascular volume. The T 1/2 of CNTO 8212 was significantly (p < 0.05) longer (by about 2.7-fold) than that for CNTO 1119 after IV administration in cynomolgus monkeys. These results show that CNTO 8212 has a slower systemic clearance and longer half-life than typical IgG1 mAbs in cynomolgus monkeys [7, 20] .
The absorption rate constants and absolute bioavailability (F) values of CNTO 1119 and CNTO 8212 were relatively high (F of approximately 75-84%) after SC administration in cynomolgus monkeys.
Prediction of CNTO 1119 and CNTO 8212 PK parameters in human beings. The population two-compartment model with IV infusion and SC administration, and first-order elimination (with proportional residual error model) adequately described the projected concentration-time data of CNTO 1119 and CNTO 8212 after IV and SC administration in human beings (figs 6 and 7). The estimated typical population PK parameter for CNTO 1119 in human beings were CL = 1.63 mL/day/kg, V 1 = 31.3 mL/kg, V 2 = 23.3 mL/kg, CL2 = 11.1 mL/day/kg, k a = 0.40 1/day, F = 0.84 and T 1/2 = 23.2 days (table 2) . In comparison, the estimated typical population PK parameter for CNTO 8212 in human beings were CL = 0.82 mL/day/kg, V 1 = 39.8 mL/kg, V 2 = 32.6 mL/kg, CL2 = 19.8 mL/day/kg, k a = 0.82 1/day, F = 0.75 and T 1/2 = 61.2 days (table 2) . These results show that CNTO 8212 is likely to exhibit a significantly slower systemic clearance and longer half-life than CNTO 1119 in human beings. The absolute bioavailability CNTO 8212 is expected to be high and comparable to that of CNTO 1119 after SC administration in human beings.
Potential multiple dosage regimens for clinical evaluation.
Pharmacokinetics simulations based on the population twocompartment model showed that SC administration of 25 mg every 8 weeks of CNTO 1119 and 25 mg every 12 weeks of CNTO 8212 will provide trough serum concentration at steady state of 1.37 lg/mL and 2.30 lg/mL, respectively (Fig 8) . These potential dosage regimens for CNTO 1119 and CNTO 8212 are likely to provide systemic exposures that may elicit PD responses in human individuals. Assuming that both dosage regimens are well tolerated, the 25 mg every 12-week dosage regimen for CNTO 8212 will permit less frequent The typical population PK parameters estimated for each mAb were clearance (CL), volume of distribution of central compartment (V 1 ), volume of distribution of peripheral compartment (V 2 ), intercompartmental clearance (CL2), first-order absorption rate constant (k a ) and absolute bioavailability (F). The terminal half-life (T 1/2 ) was also calculated. CNTO 1119 appeared to be higher compared with that of CNTO 8212 at equivalent doses. To explore the relative contribution of clearance and volume of distribution on the prolongation of T 1/2 of CNTO 8212, the effect of FcRn binding affinity on CNTO 1119 and CNTO 8212 biodistribution was investigated using 3 H-N-succinimidyl propionate (NSP) labelling technique and quantitative whole-body autoradiography (QWBA) after mAb administration in hFcRn transgenic mice [24] . The results showed that the general biodistribution patterns of CNTO 1119 and CNTO 8212 were similar although the biodistribution of CNTO 8212 appeared to be enhanced in certain tissues (adrenal gland and skin) compared with CNTO 1119 and not enhanced in other tissues (brain and adipose tissue) in hFcRn transgenic mice [24] . Thus, the totality of the data suggests that the prolongation of T 1/2 of CNTO 8212 was largely due to a decrease in its systemic clearance in cynomolgus monkeys. It is anticipated that the increased terminal half-life of CNTO 8212 may prolong the duration of its pharmacodynamics activity compared with CNTO 1119 since the LS(Xtend) mutation increased the half-life of CNTO 1119 variant with no change in biological activity. CNTO 8212 and CNTO 1119 neutralize the OSM-gp130 interaction with identical affinities (9 pM) for human OSM. The two antibodies also have comparable activity in the A375-S2 proliferation assay, completely neutralizing the antiproliferative activity of 2 ng/ml huOSM with IC 50 values of 83 (CNTO 8212) and 101 pM (CNTO 1119). Additionally, both antibodies equally neutralize the cytokine release into blood induced by intraperitoneal injection of human OSM into mice (Janssen R&D unpublished data). Thus, the two antibodies were differentiated only by increased antibody affinity for both cynomolgus monkey and human FcRn, and extended half-life in cynomolgus monkey as a result of the LS(Xtend) mutation. This investigation provides another example of the impact of half-life extension technologies on PK and supports published reports indicating that the incorporation of the LS(Xtend) mutation into the IgG1j scaffold increased the affinity of an anti-VEGF mAb (bevacizumab) for both human and cynomolgus monkey FcRn by approximately 11-fold and extended the serum half-life of bevacizumab from 9.7 to 31.1 days in cynomolgus monkeys [6] . Increasingly, targeted Fc mutations of monoclonal antibodies have been utilized to modulate IgG-FcRn interactions and PK in preclinical studies in cynomolgus and in human beings [1] [2] [3] [4] [5] [6] [7] [14] [15] [16] [17] . The Fc mutations that increase FcRn binding at pH 6.0 ensure efficient recycling of IgG and extension of half-life. Thus, the LS(Xtend) mutation presents an attractive option to modulate the PK of IgG1 mAbs, and to potentially reduce the dosing frequency, and provide wider range of dosing options in the clinical setting.
The results from this investigation demonstrate that CNTO 8212 has a longer half-life and slower clearance than typical The typical population PK parameters estimated for each mAb were clearance (CL), volume of distribution of central compartment (V 1 ), volume of distribution of peripheral compartment (V 2 ), intercompartmental clearance (CL2), first-order absorption rate constant (k a ) and absolute bioavailability (F). The terminal half-life (T 1/2 ) was also calculated.
IgG1 mAbs in cynomolgus monkeys [3] . [24] [25] [26] [27] . The median T max was approximately 4 days after dosing, and absolute bioavailability (F) was high following a single SC dose of 3 mg/kg and/or 5 mg/kg of CNTO 8212 in cynomolgus monkeys. Thus, the SC absorption of CNTO 8212 was slow, but in the typical range for IgG1 mAbs (with T max ranging from approximately 3-8 days in cynomolgus monkeys and human beings [18] [19] [20] . The slow absorption may be due to several factors including slow drug transport through the lymphatic system and FcRn interaction [27] . The FcRn binding may prevent IgG from catabolism in subcutaneous tissue/lymphatics or may enhance the FcRn-mediated transport across the vascular endothelium. Deng and coworkers [5] showed an increased SC bioavailability in mice with an IgG variant with increased FcRn affinity at pH 6.0 as compared with wild-type IgG1 (94.7 versus 76.3% for wild-type mAb), whereas an IgG1 variant devoid of FcRn binding had the lowest bioavailability (41.8%). However, a clear trend on improved SC bioavailability of mAbs was not shown for IgG1 mAbs with increased FcRn binding in cynomolgus monkeys [5] . In the present study, it appears that the T max and absolute bioavailability of CNTO 8212 were not significantly impacted by the Fc mutation and increased FcRn binding as the rate and extent of its absorption were high and comparable to that of the wild-type (CNTO 1119) and other IgG1 mAbs [18] [19] [20] . However, it should be noted that some differences were observed in the systemic exposures of CNTO 8212 from the two PK studies in cynomolgus monkeys. For example, the systemic exposures of CNTO 8212 (C max and AUC inf ) after adjusting for dose appear to be higher in study 2 compared with study 1 in cynomolgus monkeys. The differences in study design between study 1 and study 2 may account, at least in part, for the observed differences in exposures for CNTO 8212 from the two studies. Study 1 only examined the PK of CNTO 8212 at one dose level in a small number of animals and utilized PK sampling times (up to 60 days after dosing) that were probably not sufficient to thoroughly characterize the PK profile. In contrast, study 2 was a more definitive study that thoroughly characterized the PK of CNTO 8212 at four dose levels (IV and SC) and utilized more comprehensive PK sampling times (up to 126 days) after dosing. Furthermore, the systemic exposure is likely to be underestimated for molecules with slow absorption and long terminal half-lives when sampling times are not sufficient as in study 1. The differences in systemic exposures between the two studies may also be attributed to interstudy and interassay variability. In study 1, the concentrations of CNTO 8212 in cynomolgus monkey serum were determined using a qualified fit-for-purpose ECL method, while the concentrations of CNTO 8212 in cynomolgus monkey serum in study 2 were determined using a fully validated ECLIA method.
The species time-invariant approach and PK data from cynomolgus monkeys were used for the prediction of CNTO 1119 and CNTO 8212 PK parameters in human individuals. The predicted CL suggests that CNTO 8212 will be eliminated slowly with a long terminal T 1/2 in human beings. Multipledose studies of CNTO 8212 in cynomolgus monkeys will be necessary to assess the tolerability, toxicokinetic and immune response profiles prior to first-in-human studies. The predicted human PK profile and results from non-clinical studies will be used to guide dose selection and the design of the FIH study of CNTO 8212 in healthy individuals. Based on in vitro activity of CNTO 1119 and CNTO 8212 to neutralize the antiproliferative activity of human OSM, a target trough concentration of about 1 lg/mL or greater in human serum may lead to inhibition of OSM signalling in vivo. Although extrapolation of in vitro data to human individuals is unclear, dosing regimens that can maintain trough concentrations of CNTO 1119 or CNTO 8212 of ≥1.0 lg/mL in human individuals while remaining within the exposures observed at the NOAEL in the toxicology studies may be evaluated in clinical studies. PK simulations suggest that SC administration of 25 mg every 8 weeks of CNTO 1119 and 25 mg every 12 weeks of CNTO 8212 will provide the desired trough serum concentration at steady state, and are likely to elicit PD responses in human individuals. Thus, the longer half-life of CNTO 8212 may permit less frequent administration compared with CNTO 1119 in the clinical setting.
In summary, this study demonstrated that LS(Xtend) mutation decreased systemic clearance by 50% and increased the terminal T 1/2 of CNTO 8212 by 2.7-fold compared with the parent IgG1 mAb (CNTO 1119) in cynomolgus monkeys. The results of this investigation also show that CNTO 8212 exhibits linear PK characteristics after a single IV dose in the 1-20 mg/kg dose range in cynomolgus monkeys. The predicted human PK parameters of CNTO 8212 along with results from multiple-dose toxicology studies may be used to guide dose selection and the design of the FIH study of CNTO 8212 in healthy individuals. Furthermore, the increased serum half-life of CNTO 8212 is expected to provide less frequent dosing options for patients with chronic immune-mediated inflammatory diseases in the clinical settings.
